Asset sale Announced Sponsor buyer
Subsidiary of Piramal Pharma acquisition of Worldwide rights to Kenalog
US$35m consideration
Announced 8 Apr 2026
Advisers
Worldwide rights to Kenalog
Target
Not disclosed
Subsidiary of Piramal Pharma
Acquirer
- Legal adviser
- Target
- Worldwide rights to Kenalog
- Acquirer
- Subsidiary of Piramal Pharma
- Sponsor
- Piramal Pharma
- Seller
- Bristol-Myers Squibb
- Buyer based in
- India (unverified)
- Seller based in
- United States
- Sector
- Pharma
In the league tables
Similar deals
- Cosette Pharmaceuticals acquisition of Assertio non-Rolvedon assets (Indocin, Sympazan, Sprix, Cambia, Zipsor, Otrexup) Apr 2026 · US$35m · Pharma
- Harrow acquisition of TYRVAYA (varenicline solution) nasal spray 0.03 mg Aug 2026 · US$30m · Pharma
- TELI Pharmaceuticals and Telomir Pharmaceuticals merger US$47.1m · Biotech
- Aurinia Pharmaceuticals acquisition of Kezar Life Sciences Mar 2026 · US$51.5m · Biotech
- Esperion Therapeutics acquisition of Corstasis Therapeutics Mar 2026 · US$75m · Pharma
Sources
- 8 Apr 2026 Goodwin Guides Piramal on Acquisition of Kenalog® goodwinlaw.com
